Publications by authors named "W Okamoto"
Purpose: Human epidermal growth factor receptor 2 (HER2)-targeted therapies have shown promise in treating -amplified metastatic colorectal cancer (mCRC). Identifying optimal biomarkers for treatment decisions remains challenging. This study explores the potential of artificial intelligence (AI) in predicting treatment responses to trastuzumab plus pertuzumab (TP) in patients with -amplified mCRC from the phase II TRIUMPH trial.
View Article and Find Full Text PDFPurpose: HER2-targeted therapies in ERBB2-amplified metastatic colorectal cancer (mCRC) are effective; however, a notable portion of patients do not respond to treatment, and secondary resistance occurs in most patients receiving these treatments. The purpose of this study was to investigate determinants of treatment efficacy and resistance in patients with ERBB2-amplified mCRC who received HER2-targeted therapy by analyzing multiomics data.
Experimental Design: We investigated genomic data from a nationwide large cancer genomic screening project, the SCRUM-Japan project.
Article Synopsis
- Patients with unresectable or recurrent biliary tract cancer (BTC) have limited treatment options after progressing on a gemcitabine regimen, and the role of HER2-targeting therapies is not well-understood.
- A phase II trial in Japan used trastuzumab deruxtecan (T-DXd) in patients with HER2-positive and HER2-low BTC, with the primary goal of achieving a minimum objective response rate (ORR) of 15%.
- Out of 32 patients, those with HER2-positive BTC showed a confirmed ORR of 36.4%, meeting the trial's endpoint, while safety concerns included anemia, neutropenia, and notable cases of interstitial lung disease requiring close monitoring.
Aim: Atezolizumab plus bevacizumab combination therapy (Atezo + Beva) is used as the first-line therapy for unresectable hepatocellular carcinoma (u-HCC). Serious adverse events (AEs), including rupture of esophagogastric varices, have been seen during treatment. Therefore, the relationships of efficacy, safety, and portal hypertension (PH) were analyzed.
View Article and Find Full Text PDF